🇺🇸 FDA
Pipeline program

Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

Southwest Hospital, China

Phase 2 mab active

Quick answer

Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells for Lymphoma, Large B-Cell, Diffuse is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Lymphoma, Large B-Cell, Diffuse
Phase
Phase 2
Modality
mab
Status
active

Clinical trials